H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research Report) today and set a price target of $7.00. The company’s shares opened today at $4.47.
Pantginis covers the Healthcare sector, focusing on stocks such as Panbela Therapeutics, Celldex, and PDS Biotechnology. According to TipRanks, Pantginis has an average return of -5.4% and a 34.47% success rate on recommended stocks.
Currently, the analyst consensus on Armata Pharmaceuticals is a Moderate Buy with an average price target of $7.00.
See today’s best-performing stocks on TipRanks >>
Based on Armata Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $14.49 million. In comparison, last year the company had a GAAP net loss of $8.81 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Read More on ARMP:
